Refametinib

Search with Google Search with Bing

Information
Drug Name
Refametinib
Description
Entry(CIViC)
4
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
melanoma BRAF V600 BRAF V600 C Predictive Supports Resistance Somatic 2 23434733 Detail
colorectal cancer KRAS MUTATION KRAS MUTATION C Predictive Does Not Support Sensitivity/Response Somatic 2 23434733 Detail
uveal melanoma GNAQ Q209 GNAQ Q209 C Predictive Supports Sensitivity/Response Somatic 2 23434733 Detail
hepatocellular carcinoma KRAS MUTATION KRAS MUTATION B Predictive Supports Sensitivity/Response Somatic 2 25294897 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
Phase I trial of the mitogen-activated protein kin... BRAF BRAF V600 BRAF V600 Resitance or Non-Reponse true CIViC Evidence detail
Phase I trial of the mitogen-activated protein kin... KRAS KRAS MUTATION KRAS MUTATION Sensitivity false CIViC Evidence detail
Phase 1 study of MAPK1/2 inhibitor BAY 86-9766. 53... GNAQ GNAQ Q209 GNAQ Q209 Sensitivity true CIViC Evidence detail
Phase 2 study in Asian patients with unresectable ... KRAS KRAS MUTATION KRAS MUTATION Sensitivity true CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT02346032 Completed Phase 2 Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma June 30, 2015 October 13, 2016